CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-11-26): Increased serum caspase activity marks HCV-associated liver damage

Clinical

Increased serum caspase activity marks HCV-associated liver damage

Last Updated: 2004-11-26 12:00:02 -0400 (Reuters Health)

NEW YORK (Reuters Health) - In patients with chronic hepatitis C virus (HCV) infection, detection of apoptotic caspase activation in sera is a sensitive method of detecting early HCV-associated liver, especially in patients with normal aminotransferase levels, researchers in Germany report in the November issue of Hepatology.

Liver damage, caused by alcohol abuse, HCV infection, or other insults, is mediated by hepatocyte apoptosis, which in turn is mediated by intracellular cysteine proteases or caspases, Dr. Klaus Schulze-Osthoff from the University of Dusseldorf noted in comments to Reuters Health.

Having previously shown that these caspases are strongly activated in liver biopsies from HCV-infected patients, the investigators looked for caspase activation in sera from 59 patients with chronic HCV infection and 7 healthy controls.

Using a novel ELISA that detects the liver-specific caspase-cleaved substrate of cytokeratin-18 (CK-18), they were able to show that sera from HCV patients contains "considerably higher" levels of caspase activity than healthy controls.

"While 27% of patients with chronic HCV infection showed normal aminotransferase levels despite inflammatory and fibrotic liver damage, more than 50% of those patients exhibited already elevated serum caspase activity," they report.

Moreover, liver biopsy findings from patients with normal aminotransferase levels showed that elevated caspase activity was significantly associated with stage 2 or higher fibrosis.

"Routine measurement of HCV-related liver damage includes mostly the measurement of liver transaminases in sera," Dr. Schulze-Osthoff said. "However, these surrogate markers detect very late stages of liver damage and approximately 25% to 30% of patients have persistently normal serum transaminases."

These findings, the authors of an editorial write, suggest that identification of CK-18 in blood may help spot patients with aggressive disease despite normal aminotransferases and may provide a valuable tool and legitimate endpoint for assessing anti-HCV therapies.

They also suggest that HCV is an apoptotic liver disease, implying that antiapoptotic therapy may help prevent HCV-related liver disease, Drs. Ariel E. Feldstein and Gregory J. Gores from the Mayo Clinic in Rochester, Minnesota, point out.

Hepatology 2004;40:1044-1045,1078-1087.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.